Akebia Therapeutics, Inc. (AKBA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 150M 300M 450M FY14: 0 FY15: 0 FY16: 1.5M FY17: 181.2M FY18: 207.7M FY19: 335M FY20: 294.6M FY21: 211.7M FY22: 292.5M FY23: 194.6M FY24: 160.2M FY25: 236.2M FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

-80M 0 80M 160M 240M FY18: 200M FY19: 189.7M FY20: -1.8M FY21: 61M FY22: 206.9M FY23: 120.5M FY24: 97M FY25: 196.7M FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-450M -300M -150M 0 150M 300M 450M FY12: -8.5M FY13: -15.9M FY14: -37.9M FY15: -61.5M FY16: -136.5M FY17: -76.7M FY18: -178.2M FY19: -286.3M FY20: -377.8M FY21: -264.5M FY22: -80.8M FY23: -46.3M FY24: -50.5M FY25: 23.5M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-450M -300M -150M 0 150M 300M 450M FY12: -8.2M FY13: -13.2M FY14: -37M FY15: -60.7M FY16: -135.7M FY17: -73.7M FY18: -143.6M FY19: -279.7M FY20: -384.8M FY21: -282M FY22: -94.2M FY23: -51.9M FY24: -69.4M FY25: -5.3M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 150M 300M 450M FY18: 7.8M FY19: 145.3M FY20: 296.5M FY21: 150.7M FY22: 85.6M FY23: 74.1M FY24: 63.2M FY25: 39.5M FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-270M -180M -90M 0 90M 180M 270M FY12: -7.2M FY13: -11.3M FY14: -27.5M FY15: -52.4M FY16: 57.9M FY17: -56.2M FY18: -97.5M FY19: -257.4M FY20: -110.4M FY21: -253M FY22: -73.2M FY23: -23.4M FY24: -40.7M FY25: 68M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-270M -180M -90M 0 90M 180M 270M FY13: -11.4M FY14: -27.7M FY15: -52.8M FY16: 55.2M FY17: -57.8M FY18: -99.1M FY19: -264.1M FY20: -110.7M FY21: -253M FY22: -73.3M FY23: -23.4M FY24: -40.7M FY25: 67.7M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 90M 180M 270M FY19: 118.4M FY20: 138.5M FY21: 165.9M FY22: 182.8M FY23: 187.5M FY24: 210.9M FY25: 257.2M FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-180.00 -120.00 -60.00 0.00 60.00 120.00 180.00 Q4 '13: -132.12 Q1 '14: -172.40 Q2 '14: -69.60 Q3 '14: -58.15 Q4 '14: -44.75 Q1 '15: -1.91 Q2 '15: -1.92 Q3 '15: -2.13 Q4 '15: -2.27 Q1 '16: -2.44 Q2 '16: -2.99 Q3 '16: -3.27 Q4 '16: -3.60 Q1 '17: -4.05 Q2 '17: -3.63 Q3 '17: -3.16 Q4 '17: -1.86 Q1 '18: -1.19 Q2 '18: -1.26 Q3 '18: -1.23 Q4 '18: -2.41 Q1 '19: -2.55 Q2 '19: -2.44 Q3 '19: -2.44 Q4 '19: -2.36 Q1 '20: -2.21 Q2 '20: -3.00 Q3 '20: -2.96 Q4 '20: -2.77 Q1 '21: -2.75 Q2 '21: -1.98 Q3 '21: -1.90 Q4 '21: -1.70 Q1 '22: -1.60 Q2 '22: -0.94 Q3 '22: -0.89 Q4 '22: -0.53 Q1 '23: -0.33 Q2 '23: -0.54 Q3 '23: -0.33 Q4 '23: -0.29 Q1 '24: -0.23 Q2 '24: -0.21 Q3 '24: -0.23 Q4 '24: -0.34 Q1 '25: -0.22 Q2 '25: -0.18 Q3 '25: -0.08 Q4 '25: -0.02 Q1 '26: -0.08 Q2 '26: -0.11 Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.